Vetoquinol has introduced a new smaller pack size for Reprocine, to help prevent wastage. The new 6 x 10ml pack is now available from wholesalers.
Reprocine is licensed in the cow for uterine atony during the puerperal (post-parturient) period, placental retention as a consequence of uterine atony and initiation of milk ejection in a stress-induced agalactia or in conditions requiring udder emptying. In the sow, Reprocine is licensed for uterine atony during the puerperal period also, supportive therapy of mastitis-metritis-agalactia (MMA) syndrome, initiation of milk ejection and for shortening of parturition period. Reprocine is an intraveneous or intramuscular injection and has the added advantage of no milk or meat withdrawal.
Susan Mitchell, Vetoquinol's Large Animal Product Manager said: "The new pack size reduces wastage which provides an instant cost-effective advantage.
"Reprocine is rapidly distributed and slowly eliminated. Efficient parturition and milk ejection is essential for newborn welfare and ultimately provides an economic benefit. Reprocine can be utilised in many reproductive associated conditions."
Reprocine is also available in 50ml bottles.
The 'Vet REACT Colic Champions', which is being supported by 62 veterinary practices around the country, will help horse owners create a plan of action if their horse develops critical colic and needs referral to an equine hospital.
The campaign follows research conducted by the University of Nottingham which found that one in three emergency call-outs by vets were due to colic and 90% of owners were not confident in spotting its early signs.
Emmeline Hannelly, Welfare Education Manager at the BHS said: "It’s fantastic that so many vets are supporting our 'Vet REACT Colic Champions' scheme – we are delighted to be working with them. We hope that it will help even more owners to make informed decisions related to colic and in turn, improve equine welfare.”
Sarah Freeman, Professor of Veterinary Surgery at the School of Veterinary Science and Medicine, University of Nottingham said: "We are delighted to be working with vet practices on the 'Vet REACT Colic Champions' scheme. Their support and guidance has been a huge help in reaching such a wide population and we hope we can reach even more people in the future."
Alex Kingdon, BVM BVS MRCVS from Avonvale Equine Practice said: "Being part of the 'Vet REACT Colic Champions' scheme is incredibly important to our practice. Colic is by far one of the most common emergency conditions we see and the scheme has already had a huge impact on many horse owners.”
For further details on the 'Vet REACT Colic Champions' scheme and 'React Now to Beat Colic' campaign, visit: www.bhs.org.uk/colic
Photo: Shutterstock/PJ Photography
Vetsonic has taken over the marketing of Cavalesse, the oral nutritional supplement for horses that are prone to skin allergies, such as sweet itch.
Cavalesse contains a formulation of water-soluble vitamins and minerals, administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat. Vetsonic claims the supplement helps horses maintain a healthy skin and promotes normal immune function.
Ray Rochester, Managing Director of Vetsonic said: "It's an exciting phase in the development of Vetsonic which will see us rapidly expanding in the increasingly competitive small animal and equine market. Cavalesse is a welcome addition to our portfolio."
For further information, contact Vetsonic customer services on 01653 695333.
Fort Dodge Animal Health has announced that its Duvaxyn WNV vaccine against West Nile Virus (WNV) is now available in the UK, following its licensing through the European Medicines Agency (EMEA).
Duvaxyn WNV is the first vaccine available in Europe to protect horses against this emerging disease threat. 288 horses and two people in Italy were found to be infected with WNV during the outbreak that hit northern Italy in late 2008 where it is now considered endemic. The disease is endemic in all areas of North America where it has claimed the lives of both horses and humans.
West Nile Virus is caused by a highly contagious flavivirus, which is transmitted by mosquitoes, primarily of the Culex species. The natural hosts of West Nile virus are birds, with migratory birds from Africa carrying the disease. Mosquitoes become infected after taking a blood meal from infected birds and then may transmit the disease to horses and even humans. While horses are 'dead end hosts,' the consequences can be severe as the virus causes encephalitis or meningitis. Mortality rates among horses which develop neurological signs are high and there is no palliative cure for the disease. Treatment is limited to symptomatic relief which can be long and expensive.
Sabrina Jordan, UK Business Manager for Equine Vaccines at Fort Dodge said: "WNV is an increasing threat to the equestrian sector in the UK and is a particular challenge for owners who transport their horses around the world.
"The fact that a vaccine is now available will undoubtedly offer peace of mind to the equestrian community. They can be reassured that horses in the UK can now be vaccinated against WNV with a vaccine that has already been shown to be highly effective in protecting horses in America.
"With any vaccine, a record that a horse has been vaccinated with Duvaxyn WNV should be recorded in its horse passport. By presenting this vaccine in pre-filled syringes with Infovax-ID labels, we've aimed to make both the administration and record keeping of Duvaxyn WNV as convenient as possible.
"To build understanding of this potentially fatal disease threat, we are continuing to work with governments and authorities at a national and European level, as well as working in partnership with the UK's veterinary community to ensure that owners are fully informed about the risk WNV poses and of the benefits of vaccination."
Veterinary Insights has announced that it will be unveiling Vet Viewer, its new veterinary benchmarking service, at the SPVS/VPMA event at the Celtic Manor Resort, Newport, South Wales on January 22-24.
As those familiar with the old Fort Dodge Indices will be aware, benchmarking services like these allow participating veterinary practices to compare their own activity and business results against a broad panel of similar veterinary practices so that they can better gauge their own market performance and make changes to their working practices as they see fit.
Vet Viewer is provided free of charge to participating vet practices. It delivers monthly information to help practices get a quick understanding of key business metrics and a clear view of practice activities and the income they are generating.
Veterinary Insights' Managing Director Alexander Arpino said: "The Benchmarking Service has been carefully designed to give practical business support to veterinarians and we have had a great response from the 100 plus clinics that have signed up to the service to date. We have plans to expand the range of services offered to enable an even wider range of meaningful data and KPIs for veterinarians to manage their businesses."
The incoming President of the Society of Practising Veterinary Surgeons (SPVS), Nick Stuart said: "We have been working closely with Veterinary Insights for over a year on this valuable service and we are delighted to say that SPVS members will have access to additional features that track practice profitability and other important financial measurements."
For further information contact Veterinary Insights on 01403 800135 or visit: www.vetviewer.co.uk
Additionally you can download a detailed brochure on the Benchmarking Service here: http://www.vetviewer.co.uk/downloads/vet-viewer-brochure.pdf
BVA has added its voice to the Labelling Matters campaign for the introduction of mandatory method of production labelling of meat and dairy products. This would help consumers across the UK to answer the simple questions "How was this animal kept?" and "Did this animal die a humane death?", including stunning before slaughter.
A key element of the Labelling Matters campaign is that mandatory method of production labelling must be underpinned by robust welfare outcome safeguards, with on-farm welfare assessments ensuring that high welfare standards are being achieved.
Legislation for mandatory method of production labelling has been implemented already for shell eggs, which must legally be labelled either as “eggs from caged hens”, “barn eggs”, “free range” or “organic”. Labelling Matters wants to see this principle extended to meat and dairy products from other farmed animals.
The BVA highlights evidence which shows that consumers in the UK and across Europe want clear food labelling with information about animal welfare:
BVA President Sean Wensley said: "For vets it's a top priority that the animals we rear for food have a good life and a humane death. Research shows that vets are not alone in caring about where their food comes from. Mandatory method of production labelling makes sense on a number of fronts: consumers can be clearly and consistently informed about how the animals reared for their meat and dairy products were kept, with on-farm welfare assessments assuring high standards. Mandatory method of production labelling would give unambiguous information to the high numbers of consumers who care about animal welfare when buying meat and dairy products and help ensure market support for British farmers who pride themselves on achieving the highest welfare standards."
The company says it has been working hard to ensure improved supply on a number of brands including Apoquel, Palladia and now Trocoxil, with animal welfare being the key consideration at all times throughout this process.
Ned Flaxman, business unit director for companion animal, equine and innovation at Zoetis said: “It was a really difficult decision to stop production of Trocoxil in favour of Apoquel and Palladia but we felt that it was the right thing to do on animal welfare grounds. As soon as we had full stocks of these products we resumed the manufacture of Trocoxil and I am delighted to say that it will be back in stock in December.
"I would like to thank our veterinary clients for their patience and reassure them that we brought the product back to market as quickly as we could and do not anticipate any further stock issues."
Trocoxil chewable tablets are used for the treatment of pain and inflammation associated with degenerative joint disease in dogs aged 12 months or over.
For more information, contact your Zoetis account manager.
The College says that 1CPD has been designed to facilitate the new outcomes-focused CPD model which was introduced in 2020 and becomes mandatory from 2022.
An important part of this new model is reflection, so 1CPD encourages vets to reflect on the quality, relevance and impact of their CPD activities.
Dr Linda Prescott-Clements, RCVS Director of Education said: "Although the outcomes-focused element of these changes won’t become mandatory until January 2022, we recommend that you incorporate reflection in your cycle of planning, doing and recording CPD as soon as possible, and our new 1CPD app makes this much easier to do than before.
"Research has found that reflection enhances the quality, impact and relevance of CPD as professionals consider what they have learned, how they will apply their learning and how it will improve their practice. To support this CPD model, which research has shown has a positive impact on both professionalism and patient outcomes, the 1CPD platform facilitates reflection by allowing you to record your reflective notes on your recorded CPD activities, through a variety of means including text, audio or uploading a document."
The old PDR was taken offline last Friday and all of the data saved in the PDR has been transferred to 1CPD.
The 1CPD app is now available for both Apple and Android devices, available on and off line, and through a new dedicated website, all of which is now accessible using the same credentials used to access My Account.
Richard Burley, RCVS Chief Technology Officer, said: "1CPD provides a range of enhancements to RCVS’ previous offerings in this space and represents an important step forward in the College’s digital approach. Built on the latest best-practice technologies, it improves on every aspect of our previous approach to CPD support, delivering the first stage of a new, integrated, career-long CPD support capability for members.”
The launch of 1CPD also coincides with a change to the way that the College assesses CPD compliance, moving to an annual CPD requirement of 35 hours a year for veterinary surgeons and 15 hours a year for veterinary nurses.
More information on the CPD changes, along with accompanying resources, can be found on the RCVS website: http://www.rcvs.org.uk/cpd2020.
So that practices can make sure everyone in their team is aware of the changes, the RCVS has also produced a poster which can be downloaded at: https://www.rcvs.org.uk/news-and-views/publications/cpd-poster/.
For more information, contact the Education team on 0203 795 5595. For technical advice about 1CPD, email the RCVS at onecpd@rcvs.org.uk.
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
The new app has been specifically developed for CVS, is unique to the group, and is owned by the company.
It is powered by LocumBell technology.
When registering on the app, locums can input their work preferences - including their skills, desired travel radius and preferred shift times - so that they are only served up shift advertisements relevant to them.
Users can also set up notifications for upcoming jobs.
The app then allows locums to set minimum shift rates, submit the rate they would like to receive for a shift and negotiate their fees directly with a practice.
Shifts can be then be booked or cancelled on the app at the touch of a button.
All upcoming booked shifts appear on the users’ calendar.
Once a shift has been completed, locums can submit the invoice for their work using the app.
The app allows locums to see every CVS practice invoice and its status, which CVS says will allow queries to be resolved quicker and payments issued faster.
The app is being rolled out to all of CVS's practices from this August.
Amy Hughes, Head of Recruitment at CVS, said: “Locum administration can be time-consuming – as locums first have to identify work, liaise with a practice and our central support team, to negotiate and book a shift, then complete all invoice paperwork.
"We wanted to remove that pain and make it easier for locums to work with us.
The app is available for Apple devices on the App Store and for Android devices on the Play Store.
For any technical difficulties or assistance, contact: support@locumbell.com or call 0161 556 7685.
If you're attending BEVA this September you can win a place on the CEVA-sponsored Equine Ski-PD break in January 2010, combining a couple of days of first class Continued Professional Development (CPD) with some excellent skiing in the Italian Alps.
The course runs from 13-17 January 2009 and the CPD will be spread over five sessions, equating to two-and-a-half days. Equine vets Jane Boswell, Henry Tremaine, Professor Bruce McGorum, Professor Peter Clegg and Dr Tim Brazil will cover the topics of tendonitis, wound management, ophthalmology, internal medicine and joint disease.
Skiing will be at Courmayeur, a traditional Alpine village on the Italian side of Mont Blanc, where all levels of ability, from beginners to experienced off-piste skiers, can be catered for.
To win your place, which includes flights and four nights b&b accommodation, simply visit the CEVA stand at BEVA and answer a questionnaire on Tildren®, CEVA's bisphosphonate-based treatment for equine bone disease, based on information provided via a short film loop that will be running on the stand.
For further information on equine Ski-PD contact the organisers: ben.mayes@equinevetpractice.co.uk or henry.tremaine@bristol.ac.uk
The RCVS has announced that its new Royal Charter, which recognises veterinary nursing as a profession, is due to come into effect early next year once it has been signed by Her Majesty the Queen and received the Great Seal of the Realm.
The Charter, which was approved at a meeting of the Privy Council on 5 November, sets out and clarifies the objects of the RCVS and modernises its regulatory functions.
The Charter will also confirm the role of the College as the regulator of veterinary nurses and give registered veterinary nurses the formal status of associates of the College.
In addition, the Charter will also underpin other activities of the College such as the Practice Standards Scheme.
One of the key changes is that those qualified veterinary nurses who are currently on the List will automatically become registered veterinary nurses. This means that they will be required to abide by the Code of Professional Conduct for Veterinary Nurses, will be held accountable for their actions through the RCVS disciplinary process and will be expected to keep their skills and knowledge up-to-date by undertaking at least 45 hours of continuing professional development (CPD) over a three-year period.
In addition, the Charter will give formal recognition for VN Council to set the standards for professional conduct and education for veterinary nurses.
Kathy Kissick RVN, the current chair of VN Council, said: “A Charter which recognises veterinary nursing as a fully regulated profession is something that many veterinary nurses, as well as the British Veterinary Nursing Association, have been wanting for some time so I commend this development.
“This can only be a good thing for the profession, the industry as a whole and animal welfare because it makes sure that registered veterinary nurses are fully accountable for their professional conduct and are committed to lifelong learning and developing their knowledge and skills.
“Furthermore, the new Royal Charter is a significant step towards attaining formal, statutory protection of title, which would make it an offence for anyone who is not suitably qualified and registered to call themselves a veterinary nurse.”
From next autumn those former listed veterinary nurses who have become registered veterinary nurses will be expected to confirm that they are undertaking CPD and will also need to disclose any criminal convictions, cautions or adverse findings when they renew their registration.
A detailed set of frequently asked questions for listed veterinary nurses who will become registered veterinary nurses once the Charter is implemented can be found at www.rcvs.org.uk/rvn.
Although the date for signing and sealing the Charter has not yet been confirmed, once it comes into effect the College will be contacting all listed veterinary nurses by letter to outline the changes as well as putting an announcement on www.rcvs.org.uk.
Virbac has launched the BackHome Mini Chip, a microchip which is 8mm long compared to the existing standard which is 12mm.
The new Mini Chips are made of a pharmaceutical grade glass with an anti-migration coating. Because of their smaller size, they can be implanted with a needle that is 34% smaller than the standard needle. Virbac says this can minimise stress and discomfort during implantation.
Virbac has also announced a partnership with VetEnvoy, a service which works with practice management software to enable pet and owner registration details for BackHome Mini Chips to be uploaded to the Petlog database at the press of a button, saving support staff time completing online or paper application forms and reducing the number of errors.
Sarah Walker MRCVS, Product Manager, said: "Microchipping is the most effective way for owners to protect their pets and will soon become compulsory for dogs in England and Wales. Some owners are deterred from undertaking this important and simple procedure because they are concerned that it may be painful. Because our new BackHome Mini Chips are smaller and are implanted with a smaller needle, we hope that practices will be able to reassure their clients that microchipping will not cause their pet discomfort - and that the protection it offers will last a lifetime.
“Our relationship with VetEnvoy will also spare enabled practices some of the administration time spent processing microchip details, and reduce the number of mistakes in registration and any resulting complaints.
"Client information on BackHome Mini Chips is stored on Petlog, the UK's largest pet database, giving owners the best possible chance of being reunited with their pet, as long as they keep their registration details up to date."
All laying flocks that adhere to the British Lion Code of Practice must be vaccinated against Salmonella Enteritidis and Salmonella Typhimurium during the rearing period.
Environmental sampling is carried out to monitor the flocks for Salmonella infection from 22-26 weeks of age and continuing every 15 weeks throughout the laying period.
Version 8 of the British Lion Code of Practice states that approved Salmonella testing laboratories must undertake testing to differentiate between field and vaccine strains of Salmonella.
The Cevac Salmovac vaccine strain can occasionally be detected during routine sampling.
When this happens, the accredited laboratory can carry out the differentiation testing whilst also sending the samples to the official confirmatory laboratory for final identification.
Ceva says ASAP significantly improves and speeds up the differentiation between vaccine and field strains, providing early reassurance to the producer that the official confirmation will identify the vaccine strain.
The ASAP Salmonella differentiation test has 100% sensitivity and 100% specificity for differentiating the Cevac Salmovac vaccine strain from any Salmonella field strain.
Pippa Abbey, poultry national veterinary services manager at Ceva Animal Health said: “Several tests are available to differentiate Cevac Salmovac from Salmonella field strains, however using ASAP as a second medium significantly improves and speeds up the differentiation process, ensuring that laboratories can quickly and efficiently detect the presence of the Cevac Salmovac strain.
“The ASAP media is also a useful tool for monitoring Cevac Salmovac drinking water vaccination and helps with vaccination auditing.”
Ceva also says that using ASAP media as a tool for monitoring the application of its vaccine can provide reassurance that it has been given successfully.
On the day of vaccination, following priming of the drinker lines, a water sample can be taken from the end of the line and sent to the laboratory for testing.
Cevac Salmovac will grow in dark blue/purple colonies indicating vaccine availability throughout the poultry house and a good vaccination process.
Titled ‘The Five Steps of Seizure Management’, the sessions will update veterinary surgeons and nurses on:
Will Peel, Product Manager at TVM UK said: "The Lunch and Learn sessions have proved very popular with veterinary practices. Our aim is to update vets and nurses on diagnosis and management of epilepsy in general practice whilst educating them about products and services which can help them better support their patients."
TVM says it will also provided supporting literature, including guidelines and owner educational tools, designed to help veterinary staff in diagnosing and treating pets with epilepsy.
To book a Lunch and Learn, contact your local TVM UK territory manager or email help@tvm-uk.com.
The RCVS Disciplinary Committee has dismissed an application to be restored to the Register of Veterinary Surgeons from former Wirral-based vet Ian Beveridge.
In May 2013 the Committee had asked the Registrar to remove Mr Beveridge from the Register following a four-day hearing in which he was found guilty of serious professional misconduct after finding that he had treated clients badly, kept inadequate clinical records, was dishonest in his dealings with the RCVS and that animals in his care were placed at risk.
In June 2013 Mr Beveridge, who was not present or represented at the original hearing, then appealed the decision. The appeal was withdrawn in May 2014 which was when Mr Beveridge was formally removed from the Register.
Then, in April 2015, Mr Beveridge applied to be restored to the Register. The Disciplinary Committee met to consider his application in June 2015, however, this hearing was adjourned after new evidence was served to the Committee concerning allegations that Mr Beveridge had ordered prescription-only veterinary medicines when he was not authorised to do so. He was subsequently interviewed by police who took no further action.
In deciding whether Mr Beveridge was fit to be restored to the Register, the Committee heard evidence in regards to the circumstances in which the prescription-only drugs were ordered using his account and delivered to his former practice address which had been taken over by Medivet after he sold the premises to the company.
During the course of the hearing, Mr Beveridge admitted that his account had been used to buy the drugs, but that a part-time member of his staff, who was neither a veterinary surgeon nor a veterinary nurse, had done so without his prior knowledge or approval.
In relation to this evidence Ian Green, chairing and speaking on behalf of the Committee, said: "The Committee takes the view that the unauthorised use of a veterinary surgeon’s drugs account for which he carries the ultimate responsibility is a very serious matter and, of itself, demonstrates that the applicant has at best a cavalier attitude to his work which of itself means that he remains unfit to be on the Register.
"This attitude is further demonstrated by the fact that, even after the first orders were placed in late April and early May 2014, the applicant did not seek clarification from the College of his status following the withdrawal of his appeal against the original Committee’s findings."
In addition to this, the Committee also considered the seriousness of his original failings, the fact that Mr Beveridge’s acceptance of these failings was ‘qualified’, that he had been off the Register for 20 months and the fact that his efforts in terms of continuing professional development had been inadequate and not focused on those areas in need of improvement, among other factors. In mitigation it did consider that Mr Beveridge had demonstrated genuine remorse about previous actions and noted a petition and a large number of letters in support of him from former clients of his practice.
However, the Committee felt that this did not detract from the seriousness of the original failings and, in conjunction with the subsequent unauthorised ordering of veterinary drugs, that the application for restoration must be dismissed.
The 'Obesity Care in Practice' webinars are designed to help you recognise obesity, create individual weight-loss plans and turn failing cases into successful ones.
The webinars will be presented by Georgia Woods RVN, CertCFVHNut, VTS (Nutrition). Georgia is clinic nurse at the Royal Canin Weight Management Clinic at the University of Liverpool Small Animal Teaching Hospital. She has been dealing exclusively with obese pets and nutrition for the past five years.
Georgia said: “Pet obesity is on the rise and it’s one of the biggest challenges that veterinary professionals face. It reduces pets’ quality of life and leads to a range of illnesses that shorten life expectancy. This two-part webinar will help veterinarians, veterinary nurses and practice managers to effectively manage pet obesity and make a difference to the lives of their patients."
The first webinar: Obesity Care in Practice – Essential Elements, takes place on Tuesday 22nd September at 8pm.
The second webinar: Tailored plans and problem cases, takes place on Tuesday 20th October 2020 at 8pm.
To register for the free webinars, visit: https://www.thewebinarvet.com/pages/register-royal-canin-weight-management-series/
The College says that design thinking is a problem-solving process that anyone can use in all areas of veterinary practice. It is a method by which teams can create solutions to problems or challenges using empathy, creative thinking and experimentation.
The 75-minute session will give an overview of the principles behind design thinking, its various practical stages, and how it can be used to tackle challenges and problems within everyday practice.
Sophie Rogers, RCVS ViVet Manager, said: “While design thinking may sound quite theoretical and conceptual, it is actually a very practical problem-solving process that suits busy veterinary professionals and their teams. For example, the webinar will also be applying design thinking to the current backdrop of the challenges posed by Covid-19 and will be using examples that are relevant to the veterinary world to explore how it can help overcome some of these key challenges.
“The webinar will also be interactive, with delegates being sorted into small groups to carry out tasks that bring ideas to life and demonstrate how it supports innovation and working collaboratively.”
The webinar will be hosted by Gill Stevens, the Founding Director of Level Seven, a consultancy that specialises in merging coaching with design thinking methodology as a way to support innovation and team productivity, and Rick Harris, Founder of Customer Faithful, a research-led consultancy, specialising in customer research, proposition design and employee engagement.
You can sign up to the webinar, which will count towards the continuing professional development (CPD) requirement for both veterinary surgeons and veterinary nurses, via the ViVet website at: www.vivet.org.uk/design-thinking-webinar-a-practical-approach-to-problem-solving-in-veterinary-practice.
The two cases came from Bristol and Kingsbridge, Devon, taking the total number this year to five countrywide.
David Walker, American, RCVS and EBVS European specialist in small animal internal medicine, who leads the team at Anderson Moores, said: “We’re very sad to confirm two further cases of CRGV.
"Unfortunately, we find ourselves at the time of year when cases are most commonly identified."
There were 47 confirmed cases in 2020 and 28 in 2021.
The two new cases bring the total to 284 since the disease was first detected in the UK in 2012.
Anderson Moores has launched a website dedicated to Alabama Rot, which offers advice and information for owners and veterinary professionals, including a live map of confirmed cases across the UK: www.alabama-rot.co.uk.
Suicide postvention is the response and provision of support after a suicide.
It aims to support recovery, and to prevent further adverse outcomes in the aftermath including the prevention of further deaths by suicide.
The new guidance is intended for people who have been affected by the suicide of a veterinary professional, people who support those who have been affected, and for managers and leaders in veterinary workplaces who are working to prevent suicide.
The guidance examines veterinary workplace considerations after a suicide, including immediate aftermath and longer term.
It also covers communication, including talking both with colleagues and clients, and publicly on social media and elsewhere.
It finishes with a checklist of actions for veterinary workplaces affected by suicide considering immediate, short term, and ongoing actions for support and postvention.
As well as providing this guidance, Vetlife can provide individualised support to practices and individuals who have experienced a suicide through its Postvention Service.
If you are a UK veterinary professional who has been affected by suicide or wants support for a veterinary workplace, contact 0303 040 2551.
You can download the guidance here.
The update includes a new scoring system of low, moderate or high cancer risk which replaces the original numerical HDI scores and simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners.
HT Vista says the device can now categorise cancer risk levels, based on malignant probability, with a sensitivity of 90% and a negative predictive value (NPV) of 98%.
The company says this translates to a “low cancer risk” result having a malignant probability of 10% or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures.
The tool can also now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, Managing Director at HT Vista, said: "I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system.
"Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumour types, we are taking another significant step forward.
"This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes.
"By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives."
On the other end of the scale, a “high cancer risk” result has a malignant probability of 50% or more and indicates a stronger likelihood of malignancy.
HT Vista says these cases require additional diagnostic tests for mass identification.
The company highlights a big distinction between this and other screening modalities is that it can be nurse-led.
HT Vista will be on display and there will be live demonstrations at BSAVA Congress from the 20th to the 22nd of March 2025.
https://bit.ly/ht-vista-screening-tool
"Advances in Imaging of the Equine Distal Limb 2017–2022" comprises a total of 20 papers which have been selected by Mathieu Spriet, Ann Carstens and Tim Mair.
It also includes an editorial from the EVJ summarising the major historical technological developments in imaging of the foot and fetlock.
The publication looks at the evolution of computed tomography (CT), positron emission tomography (PET), which has opened a whole new field of possibilities for bone and soft tissue imaging in racehorses and sport horses, MRI and how it has been improved by optimising scanning techniques, ultrasound radiography and scintigraphy.
Mathieu Spriet said: “The content of this virtual issue represents an amazing amount of new knowledge that with no doubt will contribute to improve equine welfare and safety.
“With the increase availability and versatility of all the imaging modalities, the knowledge base appears to increase exponentially.
"We are very excited to see what the next five years will bring. We hope the readers will enjoy consulting this collection as much as we enjoyed putting it together.”
The virtual issue is free for 12 weeks and can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.equine-distal-limb
Photo: 18F-NaF PET, CT and MRI images from a horse with navicular and middle phalanx lesions. Adapted from EVJ 2018;50: 125-132
A new study, led by academics at the University of Bristol's School of Veterinary Sciences and published online in Applied Animal Behaviour Science, has investigated the occurrence of dog aggression towards people with a survey of UK dog owners.
Nearly 15,000 questionnaires were distributed to dog owners of which 4,000 were returned and used in the analysis.
The researchers found that:
The study highlighted that the majority of dogs showing aggression do so in just one of these situations. Researchers say this indicates that the common tendency to categorise dogs as either generally 'safe' or 'vicious' is a misconception, and that most dogs show aggression as a learnt response to particular situations.
Dr Rachel Casey, Senior Lecturer in Companion Animal Behaviour and Welfare, said: "Dog owners and members of the public need to be aware that any dog could potentially show aggression if it is anxious or feels threatened, even when it has never done so before.
"On the other hand, dogs which have shown aggressive signs in one situation are not necessarily 'dangerous' when in other contexts - an important consideration in the assessment of animals, such as in rehoming centres."
The study also compared the characteristics of those dogs reported to show aggression with those which had never done so. It was revealed that factors such as training classes attended, type of training method used, the sex and neuter status of dogs, the age category of owners, and the breed of dogs were all associated with the occurrence of aggression.
Different risk factors were found to be significant in statistical models examining aggression to family members and unfamiliar people. This suggests that different factors are important in the development of aggressive signs depending on the situation.
The research also highlighted that although general characteristics, such as breed type, are significant risk factors across large populations they explain only a small amount of the overall difference between aggressive and non-aggressive dogs. This suggests that it is not appropriate to evaluate the risk of aggressive behaviour in an individual dog using characteristics such as breed type.
Reference
Human directed aggression in domestic dogs (Canis familiaris): occurrence in different contexts and risk factors, Rachel A. Casey, Bethany Loftus, Christine Bolster, Gemma J. Richards, Emily J. Blackwell, Applied Animal Behaviour Science, published online 11 December 2013.
The service will be run by European and RCVS recognised specialist in Soft Tissue Surgery, Jane Ladlow, and will begin taking referrals from October 28th.
Jane has nearly 20 years’ experience as a specialist clinician, researcher, teacher and lecturer.
Her main focus for the last 10 years has been upper airway disease in dogs. As the clinical lead of the Cambridge Brachycephalic Obstructive Airway Syndrome (BOAS) Research Group, she has been instrumental in the introduction of objective, non-invasive assessments of airway function, identifying risk factors for BOAS, clinical diagnosis, breeding guidelines and the development of new surgical techniques (laser turbinectomy and laryngeal surgeries).
She has extensive experience of general surgery, and particularly enjoys oncology surgery, with an emphasis on treatments that are kind to owners and animals. Jane was the 2019 recipient of the BSAVA Simon Award for outstanding contributions in the field of veterinary surgery.
Jane said, “The team at HSR demonstrate a drive for excellence, both clinically and in providing the best experience for clients and their pets. I’m excited to start working as part of the innovative and collaborative team of surgeons, nurses and support staff.”
Director and orthopaedic surgery specialist, Michael Hamilton, said: “We’re absolutely delighted to welcome Jane to the team here. Her work has revolutionised the way we diagnose and manage BOAS. Continual learning and innovation are core to our practice, and we know Jane will be a strong driving force helping us continue providing the best outcomes for clients and their pets.”
For more information, visit: www.hamiltonspecialists.vet
The study titled “Diagnosis and treatment of gastro-oesophageal junction abnormalities in dogs with brachycephalic syndrome” included thirty-six client-owned brachycephalic dogs (French bulldogs, pug and English bulldogs) in a prospective, randomised trial.
Antacid treatment (omeprazole (1mg/kg PO q24 hours) and magaldrate (5-10mL/dog PO q8-12 hours)) was randomly prescribed in 18 dogs before and after surgery, while the other 18 dogs did not receive any gastrointestinal medical treatment.
Digestive clinical signs and gastro-oesophageal junction abnormalities (GJA) were assessed and scored at presentation, at the time of surgery and at recheck. GJA were assessed during endoscopy in standard conditions, as well as during endotracheal tube obstruction. All endoscopic procedures were recorded and reviewed by a single, blinded reviewer.
In order to assess whether endotracheal tube obstruction manoeuvre accurately detects GJA, the procedure was also performed during the examination of the gastro-oesophageal junction in a group of 10 control dogs. Control dogs were healthy or had diseases that were not expected to interfere with gastro-oesophageal junction dynamics, and were anaesthetised for independent purposes.
Dr Emilie Vangrinsven, corresponding author for the paper said: "Although results of multivariate analysis failed to demonstrate a direct effect of antacid treatment, a significant interaction between antacid treatment status and improvement of digestive clinical score throughout the endoscopies was present, meaning that treated animals seem to improve faster and have lower clinical scores after surgery than untreated animals. Furthermore, a significant improvement in GJA-obstruction score was present in the treatment group only.
"In contrast to standard endoscopy, the obstruction manoeuvre during endoscopy allowed detection of GJA in dogs, even in the absence of clinical signs. We were concerned that the obstruction manoeuvre may induce false positive results for the diagnosis of dynamic GJA; in the control group, GJA during obstruction manoeuvre were found to be negligible suggesting that this technique does not significantly overestimate the presence of GJA.”
Nicola Di Girolamo, Editor of JSAP said: "Based on this study, antacid treatment administered to brachycephalic dogs undergoing surgery may be beneficial. It should be noted that a direct influence of antacid treatment on digestive clinical and lesion scores could not be significantly demonstrated, which may have been because of the lack of an actual difference, or as a result of the small sample size.”
The full article can be found in the March issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13279
Photo: Professor Ian Ramsey